NMRA
Neumora Therapeutics, Inc.1.8500
-0.1100-5.61%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms pipeline; tox routine, navacaprant path clear.
Q&A largely reaffirmed the scripted pipeline updates, with management expressing confidence that one positive KOASTAL study plus supportive data—like anhedonia gains or safety—could prompt a pre-NDA meeting for navacaprant in MDD. On NMRA-215, tox findings were pinned on study conduct issues, a common industry hiccup; they're repeating with a new CRO and precedent supports IND clearance in Q1 2027. NMRA-898 edged out as M4 lead for schizophrenia thanks to potent CNS penetration, long half-life matching blockbusters, and clean early PD versus emraclidine. Delay trims 215 spend, freeing capital. Investors will eye Q2 navacaprant data.
Key Stats
Market Cap
314.39MP/E (TTM)
-Basic EPS (TTM)
-1.47Dividend Yield
0%Recent Filings
8-K
NMRA-511 Phase 1b data shines
Neumora unveiled Phase 1b data for NMRA-511 in Alzheimer's agitation on February 11, 2026, at Guggenheim's biotech summit. The drug showed unsurpassed CMAI effect sizes (0.51–0.64 in elevated anxiety patients) versus Auvelity and Rexulti, with mild tolerability and low discontinuations. Well tolerated. Phase 2 could target anxiety-enriched cohorts.
8-K
Neumora's 2026 pipeline catalysts
Neumora unveiled its January 2026 corporate deck at JP Morgan Healthcare, spotlighting navacaprant's Phase 3 MDD trials with joint KOASTAL-2/3 topline data due Q2 2026. NMRA-215 NLRP3 inhibitor showed up to 19% monotherapy weight loss in DIO mice, matching semaglutide while preserving lean mass. Multiple catalysts span franchises. Cash funds ops into 3Q 2027.
8-K
NMRA-511 Phase 1b success
Neumora announced positive Phase 1b results for NMRA-511 in Alzheimer's agitation on January 5, 2026, showing a placebo-adjusted -7.6 CMAI total score drop at week 6 in elevated anxiety patients (Cohen's d 0.51-0.64), with favorable safety and no somnolence. NMRA-511 packs a punch in anxiety-driven cases. Plans include higher-dose expansion and Phase 2/3 in 2026; cash funds ops into Q3 2027.
8-K
Loan converted to shares
Neumora Therapeutics converted $2.5 million of term loan principal from K2 HealthVentures into 2,849,327 common shares at $0.8774 per share on November 20, 2025, under its May 2025 Loan Agreement. This reduces debt by $2.5 million while diluting equity. Shares issued under Section 4(a)(2) exemption. Debt shrinks nicely.
8-K
Q3 loss narrows; cash funds to 2027
Neumora Therapeutics reported Q3 2025 net loss of $56.8M, down from $72.5M year-over-year, with R&D expenses dropping to $40.5M from $60.6M due to expired Amgen collaborations. Cash stands at $171.5M after drawing $40M non-dilutive debt, funding operations into 2027. Pipeline advances: NMRA-215 Phase 1 starts Q1 2026; NMRA-511 data due year-end.
ANRO
Alto Neuroscience, Inc.
17.10+0.07
CTNM
Contineum Therapeutics, Inc.
11.55-0.03
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NERV
Minerva Neurosciences, Inc
4.17+0.13
NEUP
Neuphoria Therapeutics Inc.
3.90+0.07
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60